Colorectal Cancer Trial Landscape (October 2026)

Last updated: Oct 3, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov

Overview

Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.

Mechanism Breakdown

Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.

Recently Updated Trials

NCT	Phase	Title	Mechanism
NCT04847063	1	Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies	Multiple chemotherapeutics (5-Fluorouracil, Oxaliplatin, Doxorubicin) -- cytotoxic chemotherapy
NCT07188025	3	ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer	Unknown mechanism
NCT05673148	2	Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial	Unknown mechanism
NCT07140679	2	Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer	PD-1 -- immune checkpoint inhibitor (antibody)
NCT06885697	1	Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma	Mesothelin -- chimeric antigen receptor T cell therapy (CAR T)

Top Sponsors

Sponsor	Recruiting trials
Fudan University	70
Sun Yat-sen University	54
Sixth Affiliated Hospital, Sun Yat-sen University	27
Second Affiliated Hospital, School of Medicine, Zhejiang University	15
Peking University Cancer Hospital & Institute	15

Geographic Distribution

Countries/regions with the most active trial sites for colorectal cancer. A multi-site trial is counted once per country/region.

Emerging Classes

Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.

Start	NCT	Title	Mechanism
May 6, 2027	NCT07842965	CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial	CCR5 -- monoclonal antibody (immune checkpoint inhibitor)
Dec 1, 2026	NCT07363408	Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer	PD-1 + unknown target (ADG126) -- immune checkpoint blockade + unknown mechanism
Nov 24, 2026	NCT07829588	Pharmacokinetic (PK) Study of QL1203 and Vectibix® for the Treatment of RAS Wild-type Metastatic Colorectal Cancer	EGFR -- monoclonal antibody (anti-EGFR antibody)
Nov 1, 2026	NCT07587827	Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer	Neoantigens + CTLA-4 -- personalized DNA neoantigen vaccine combined with immune checkpoint blockade (anti-CTLA4 antibody)
Nov 2026	NCT07738939	IKS04 Regimen in Advanced Solid Tumors That Express CA242	CA242 -- antibody-drug conjugate (ADC)
Oct 30, 2026	NCT07272642	A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.	LRRC15 -- radiolabeled monoclonal antibody (radioimmunotherapy)
Oct 10, 2026	NCT07627191	GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer	GLP-1 receptor -- receptor agonist (GLP-1 RA)
Oct 7, 2026	NCT07715903	Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy	Proteasome -- proteasome inhibitor (carfilzomib)

Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.